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This method uses the life table data directly to derive an empiric distribution of 
death times. Additionally, parametric survival analysis may be used to fit life table 
data. This method may be more flexible, avoiding the need to look up mortality 
hazards directly from life tables, requiring fewer parameters, and possibly sav-
ing computation time. Typically, this method is carried out by linearizing specific 
parametric survival distributions and using regression analysis on data from the 
life table to obtain estimates for the parameters of the distribution. Although this 
type of analysis is fairly straightforward, the estimates of the uncertainty around 
the parameters are inaccurate. A new method of obtaining these parameters, which 
involves simulating individual death times from the life table data and using maxi-
mum likelihood estimation to obtain the needed parameters, may be considered 
when modeling all-cause mortality. Utilizing the number of individuals at risk, this 
method may provide more accurate estimates of parameters and their uncertainty. 
The implementation, appropriateness, challenges, advantages and disadvantages 
of these three techniques when modeling all-cause mortality in health economic 
models will be discussed.
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Joint bayesian netwoRk Meta-analysis foR event counts and 
hazaRds – coMPaRison of Methods and iMPleMentations
Schmidt H., Nehmiz G.
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Networks of treatments summarize all available information about the relative 
effectiveness of several treatments, also if both direct and indirect evidence needs to 
be combined[1]. For clinical trials with survival results, some will have been reported 
based on numbers of patients with event, and some based on the hazard ratio. A 
common scale for mapping the observed effects has been proposed[2]. Treatment 
contrasts would then be estimated through Bayesian methodology based on Markov 
Chain Monte Carlo (MCMC) simulation. Similar problems arise for trials with binary 
outcome. We investigate one example from pulmology and compare two imple-
mentations of the MCMC method, WinBUGS and SAS® PROC MCMC. Moreover, we 
investigate a deterministic-numerical approximation to the distribution of treat-
ment contrasts, the integrated nested Laplace approximation (INLA) method. Of 
particular interest here is the goodness of the approximation, as the example 
dataset includes only small numbers of trials, patients and events. We show how 
to condense graphically the complex pattern of multiple treatment comparisons. 
We conclude with remarks on model selection, goodness-of-fit and the Deviance 
Information Criterion (DIC).
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liMited nuMbeR of studies
Odom D., Chirila C., Sherrill B., Wang J.
RTI Health Solutions, Research Triangle Park, NC, USA
Objectives: Meta-analysis is being conducted extensively in part due to require-
ments from health care decision-making agencies. Meta-analysis techniques con-
tinue to develop, and software now exists to model networks using Bayesian or 
frequentist approaches with study effects treated as fixed or random. The non-
model based anchored indirect-treatment comparison (AIC) method is also suit-
able for making pairwise treatment comparisons. However, practical issues emerge 
particularly when the network is comprised of a limited number of studies. Of 
special interest is the situation where a star network contains only one trial for 
a given treatment comparison. Our goal was to investigate the performance and 
interpretation of different meta-analysis methods when few studies are availa-
ble. MethOds: Example star networks anchored by placebo were created for binary 
endpoints with varying proportions and sample sizes. Generalized linear mixed 
models were fitted using PROC GLIMMIX in SAS with a random study effect. Results 
were compared to the AIC method as well as analogous Bayesian models using 
WinBUGS. Results: Estimated odds ratios were examined to identify patterns 
among methods. If placebo effects were largely different across individual trials, 
differences between methods varied depending on effect sizes and sample sizes. If 
placebo effects were similar, the frequentist random-effects model was not able to 
estimate a random study effect and it was reduced to a fixed-effect model (similar 
to the AIC). cOnclusiOns: The limitations of conducting a meta-analysis with a 
small number of trials should be understood regardless of the methodology used. In 
the special case of a star network with only one trial per treatment comparison, the 
differences between methods depend on the underlying evidence. The implications 
for interpretation will be discussed.
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Objectives: Economic evaluations in oncology built using partitioned survival 
analysis do not permit analysis of the post-progression period separately from the 
progression-free period. Moreover, when the outcomes are not complete at the 
time of the analysis, the benefits experienced by patients in the clinical trial used 
to inform the model are assumed to continue for the duration of the model due 
to extrapolation of the trial data using one set of parametric curves. The objective 
of this study is to present and contrast possible methods to address the struc-
tural uncertainty in the incremental effects and the cost-effectiveness estimates 
derived from partitioned survival models. MethOds: Options for addressing the 
long-term benefits in partitioned survival models are explored using a hypotheti-
cal economic model with three states (progression-free, progressed disease, and 
death). The methods include the standard approach of projecting treatment group 
PFS and OS outcomes using parametric survival curves, using time-varying hazard 
ratios to modify the relative benefits between treatments, calculating and modi-
fying treatment-related Markov probabilities following progression in the cohort, 
the framework is flexible enough to capture treatment effects that vary by line of 
therapy, and we demonstrate how appropriate discounting to allow for differential 
timing can still be made. We believe that the framework illustrated in this paper 
has wide applicability to sequencing models in many disease areas, most nota-
bly oncology and rheumatology where such sequencing models are common. We 
demonstrate the flexibility of the approach and show how time dependency can be 
incorporated at any sequence of the model without having to resort to individual 
patient simualation.
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Rare diseases provide a perplexing problem for reimbursement agencies. Orphan 
drug development is often incentivized by government entities. Despite these 
incentives, reimbursement at a viable level is not assured, and recent efforts by 
reimbursement bodies are changing the reimbursement paradigm substantially. 
Value-based pricing agreements, which link the price of the drug to the value 
achieved, is one such effort. However, demonstrating value for an orphan drug 
remains challenging. To better understand the potential value and therefore pricing 
of orphan drugs, we developed a comprehensive model to evaluate the pricing, eco-
nomics, reimbursement, and market strategy (PERMS) specifically for these drugs. 
The interactive simulation model was developed to combine evidence on develop-
ment costs, cost-effectiveness, treatment pathways, improvements in quality of 
life, and market share. The PERMS model was designed to evolve alongside the 
drug development process, incorporating new parameters and data as they become 
known. Extensive sensitivity analyses are performed to highlight the substantial 
uncertainty in disease prevalence and costs of the diseases. An interactive inter-
face is developed for users to examine how changes in model input values affect 
outcomes of interest. In this presentation, we will describe the primary elements 
of the PERMS model, demonstrate how the results may vary across subpopulations 
and illustrate the potential value of new drugs. Concepts will be illustrated through 
the use of real-world examples such as graft-versus-host disease (GVHD); a major 
complication of stem cell or bone marrow transplantation that has significant prog-
nostic implications in the setting of a rare resource. This presentation will illustrate 
how a holistic view through simulation modeling can be useful and informative for 
understanding disease burden and potential reimbursement levels and making a 
decision to proceed to the next phase of drug development.
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Objectives: To demonstrate how a conceptual model of symptoms of non-diabetic 
peripheral neuropathic pain, impact on quality of life and tolerability of treatments 
helps to select patient reported outcomes (PROs) in clinical trials. To show that 
the selected PROs measure what is expected. MethOds: A literature review and 
interviews with 4 clinical experts were conducted to identify the PRO measurement 
concepts related to symptoms and impacts of highest importance and relevance 
to non-diabetic peripheral neuropathic pain patients. The mechanism of action 
of treatments available and in development were also included in the conceptual 
model. Based on this information, available instruments were evaluated to assess 
if measures focusing on emerging, central concepts were available and of relevance 
to a planned Phase IV study. Results: Based on the literature review and expert 
interviews, pain was the predominant symptom concept. The most predominant 
impact concepts were difficulty with sleep quantity and quality. Available treat-
ments suggested detrimental impact on cognition and local treatment-related 
pain. Instruments that seem to measure the central concepts were numerical pain 
rating scale scale (NPRS), MOS-Sleep and MOS-Cog. Furthermore the Treatment 
Satisfaction Questionnaire for Medication (TSQM) was assessed in order to be able 
to measure treatment satisfaction comparing different medications Results of the 
chosen PROs included in a Phase IV study with patients with non-diabetic peripheral 
neuropathic pain seem to show that they are able to measure the concepts they 
were selected to assess. cOnclusiOns: The FDA PRO Guidance states that meas-
ures should be conceptually valid as they relate to the disease being studied, meet 
a threshold of psychometric soundness, and be relevant to patients. This research 
represents an important step toward establishing the PROs that could be used in 
studies with patients with non-diabetic peripheral neuropathic pain.
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The estimation of life-years is an important component of many health economic 
models and this outcome is often required by health technology assessment agen-
cies in the evaluation of health care technologies. Life-years are often obtained 
by adjusting the country-, age-, and gender-specific all-cause mortality, which 
considers all deaths in a population regardless of the cause, to account for addi-
tional deaths due to a specific disease (i.e., the disease-specific mortality). Properly 
modeling all-cause mortality and knowing the uncertainty associated with the 
estimates (if estimated) is therefore an important step in building a health eco-
nomic model. The report of the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) Modeling Good Research Practices Task Force recom-
mends modeling all-cause mortality non-parametrically based on life table data. 
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2+, 3+. States: A feature selection is executed by a modeler who decides which set 
of features describes a disease state or patient cohort best. For identifying the most 
relevant attribute combinations a cluster analysis is applied beforehand. Transitions: 
Patients remain in one particular state as long as they match the predetermined 
features and attributes. Otherwise, a change to another state occurs. Thereby, a 
sequence of states for each patient is defined. As a final step, these sequences are 
used for deriving a model structure. expected Results: Markov models backed up 
by real-life patient records. As a result of the automatic generation process models 
can be used for validating hypotheses or comparing outcomes for different patient 
cohorts. Therefore, the usage of such models is not strictly limited to health eco-
nomic analysis. A first validation indicates the feasibility of the outlined methods. 
It was possible to reconstruct a published disease model. cOnclusiOns: Ongoing 
research is conducted with focus on data quality, i.e., accuracy, completeness and 
timeliness, at the regional cancer registry.
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continuous Patient engageMent in coMPaRative effectiveness 
ReseaRch (ceR): an aPPlication in caRdiovasculaR disease (cvd)
Vandigo J., Oloyede E., Abdulhalim A.M., Mullins C.D.
University of Maryland School of Pharmacy, Baltimore, MD, USA
Objectives: A 10-step, systematic framework to enhance patient engagement 
throughout the CER process has been previously proposed. The objective of this 
research was to apply this framework in the context of CVD since CVD is the 
leading cause of death in the United States and impacts a diverse patient popu-
lation. MethOds: At each of the 10 steps in the research process, the rationale 
and means for researchers to engage CVD patients is presented. Results: When 
prioritizing CER topics, patients can inform whether resources should be allocated 
towards hypertension, a highly prevalent disease with various established thera-
peutic options, or into finding new treatment options for patients affected by pul-
monary arterial hypertension, a rare disease. Patients with CVD can also help to 
select outcomes that are meaningful from their perspective. Interest in the major 
outcomes (stroke, heart failure) will likely be balanced against patient concerns 
with treatment side effects, such as dizziness and dry cough, which can impact 
quality of life. In the latter steps of translation and dissemination, patients can 
help to tailor results under primary, secondary, or tertiary prevention and across 
racial/ethnic subgroups. cOnclusiOns: The 10-step framework can be tailored 
to engage patients with CVD. For some stages of CER, purposes and strategies for 
patient engagement for CVD are similar to many other disease states. However, 
there are unique best practices for patient engagement in CVD. Researchers should 
recognize that there is no “one-size-fits-all” approach to patient engagement and 
should engage CVD patients throughout the CER continuum.
PRM150
value of RaRe disease non-inteRventional studies to suPPoRt PayeR 
& clinical descision Making
Degun R., Patel D., Marinsek N., Chalmers M.
Navigant, London, UK
Objectives: In rare diseases and sub-populations for specialty diseases, national 
and regional payer negotiations regarding funding and reimbursement of new 
drugs can be challenging due to the lack of available robust data to inform deci-
sion making. Clinical trials designed to ensure regulatory approval often lack the 
necessary information to meet the needs of a diverse range of payer and clinical 
stakeholders across the globe. Traditional patient registries, if available, generally 
do not capture the required level of detail, especially in terms of health-economic 
data. To ensure ongoing access, new therapies to treat rare diseases require further 
real world evidence to build a strong clinical and economic case for long term 
treatment provision. MethOd: We employed a variety of traditional and innova-
tive methods to collect real-world evidence on disparate populations of patients 
with rare diseases. Retrospective chart review studies have been conducted to 
understand demographics, clinical and pathological characteristics, treatment, 
outcomes and resource use. Patient and caregiver surveys have subsequently been 
used to correlate quality of life, functional status and economic burden to patient 
treatment pathways. Results: Non-interventional studies provided a longitudi-
nal understanding of patient care pathway from diagnosis to long-term treatment 
and follow-up including the natural history of a rare disease, genotypic/phenotypic 
variability, differences in treatment patterns across countries and the clinical drivers 
of therapy use. This enabled comparison of real-world treatment practice versus 
clinical guidelines. In addition, direct and indirect costs were calculated to under-
stand the budget impact of treatment. Insights helped the manufacturer refine the 
product value proposition and provide necessary evidence to support product access 
and reimbursement. cOnclusiOns: Rare disease non-interventional studies offer 
manufacturers the opportunity to fulfill peri and post-launch evidence needs of 
regulators and payers by providing bespoke and robust real world data efficiently.
PRM151
Publication of Methodological guidelines: the develoPMent of 
systeMatic Reviews (sR) and Meta-analyses of RandoMized clinical 
tRials by the dePaRtMent of science and technology of the 
bRazilian MinistRy of health (decit/Moh)
Elias F.T.S.1, Koury C.D.N.2
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Since 2004, DECIT supports the production of SR by teaching and research institu-
tions in Brazil. However, these studies were guided by international recommenda-
tions causing some variability in the execution and presentation of results. In order 
to standardize and equalize the elaboration quality of SRs throughout Brazil, DECIT 
requested to research institute Hospital do Coração Hcor draft this guideline. The 
initiative was funded by the Support Program for the Institutional Development of 
the Brazilian Public Health System. The guideline was based on two international 
and truncating the analysis. Results: The survival outcomes produced by the 
model are presented graphically to illustrate the impact of the different methods, 
along with the magnitude of change in the incremental benefits and the resulting 
incremental cost-effectiveness ratios (ICERs) using the various methods compared 
to the standard approach. Conclusion: Capturing and quantifying the structural 
uncertainty in partitioned survival analysis is not well developed in the literature. 
This study demonstrates the considerable uncertainty and the potential for bias 
from choosing one method of extrapolating outcomes for an economic evaluation 
using a partitioned survival analysis. The study also proposes options for exploring 
the uncertainty in order to present a balanced analysis and avoid bias in economic 
evaluations for oncology research.
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the challenges of Pilot testing tRanslated PRo MeasuRes with 
childRen
Two R.1, Currie D.1, Browning R.1, Loten M.1, Herdman M.2
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intROductiOn: PRO measures aimed at child respondents are generally devel-
oped with the input of children from the target population, although in certain 
cases their age or medical condition can have implications that make this less 
feasible. This extends also to the translation and linguistic validation of these 
measures, where the usual standard of pilot testing translations with the target 
population may not be appropriate or beneficial. This presentation investigates 
the challenges of pilot testing translations with children, and explores alternative 
validation methods. bAckgROund: Current guidelines advise that translated PRO 
measures should be tested with patients from the target population to best assess 
the measures’ suitability. From our own findings, pilot testing with children can 
be very successful as they give more creative answers during cognitive interviews, 
and they can be more willing to give open, honest answers than adults. However, 
the success of pilot testing with children can vary depending on their age. Younger 
children may have too limited a vocabulary to express concepts in their own words, 
or may struggle to understand the cognitive debriefing process. Additionally, in 
some circumstances there may be ethical issues involved when asking ill children 
to decide whether to participate in this process which may be difficult for them to 
understand. AlteRnAtives: Alternative methods must aim to establish the same 
information that would be obtained from the target population: i.e., whether the 
translation is appropriate for that group. Therefore we propose review processes 
involving parents, teachers, paediatric nurses or clinicians, depending on the meas-
ure’s content and target age range. cOnclusiOn: In some cases it is possible to 
successfully pilot test translated PRO measures with children, and it can be the 
optimum solution, where practical. However, reviews by parents or suitably quali-
fied professionals are useful alternatives where testing with children might not 
be feasible.
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Quantifying the iMPact of PRogRession on suRvival in oncology: 
an aPPlication of statistical Modeling fRaMewoRk to MeasuRe the 
iMPact of events on subseQuent Risks
Ishak K.J., Proskorovsky I.
Evidera, St-Laurent, QC, Canada
In many diseases, the occurrence of a clinical event (e.g., stroke) can change the 
risk of other, usually more serious, events (e.g., death). Quantifying the impact of 
the first event and factoring this into assessment or extrapolation of the risk of the 
second event is important for clinical understanding of the disease as well as health 
economic assessments of new treatments. For instance, in oncology, understanding 
the impact of progression of disease on the risk of dying can be vital for projection of 
overall survival, which is often only partially observed in trials. Proper understand-
ing of the impact of the event requires consideration of not only the occurrence of 
the event, but also its timing and the possibility that its effect changes with time 
following the event. For instance, patients who progress early after initiation of 
treatment may be subject to a greater increase in risk of death than a patient who 
progresses, say, a year after treatment. Similarly, once progressed, the increase in 
mortality may be highest soon after the event and gradually decline among surviv-
ing patients. We will outline a statistical modeling framework designed to quantify 
these various dimensions of the impact of events using Cox regression models 
with time-dependent covariates and effects (i.e., coefficients) to reflect the timing 
of event (TE) as well as time elapsed since the event (TSE). The model produces 
estimates that have direct clinical relevance; for instance, the coefficient for TE 
provides an assessment of the benefit of delaying progression, while TSE reflects 
whether and for how long the increase in mortality is sustained and whether it 
ever returns to the level of patients who had not progressed. The parameterization 
of the model will be illustrated with example code and analyses of example data.
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autoMatic cReation of disease Models using data Mining 
techniQues on data fRoM a clinical canceR RegistRy
Pobiruchin M.1, Bochum S.2, Martens U.M.2, Kieser M.3, Schramm W.1
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Objectives: Health economic disease models are often build with data from clinical 
trials and thus do not necessarily reflect the routine care situation in hospitals. For 
this scenario, we outline a method to generate disease models using data mining 
algorithms on patient records from a regional clinical cancer registry. MethOds: 
Markov models are a common technique in decision making. Their structure of 
states and transitions reflects the progress of a disease. We define a disease state as 
a set of features which represents a specific state of illness, e.g., diagnosis of breast 
cancer in HER-2-positive (human epidermal growth factor receptor 2) women who 
are treated with chemotherapy and mastectomy. In particular, a feature can consist 
of several attributes, e.g., HER-2 status can be described with the attributes 0, 1+, 
